Allergan May Add New Non-Cosmetic Use to Botox

Allergan’s supplemental biologics license application (sBLA) for a Botox label expansion to idiopathic overactive bladder (OAB) may receive a final decision this month.

The application has a PDUFA date in January, according to estimates by Bloomberg Industries, which are based on the company’s submission in both the U.S.

Click here to continue reading.

Bloomberg BRIEF Newsletters